Literature DB >> 27831900

Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.

Pradeep Natarajan1,2,3, Nina B Gold2,4, Alexander G Bick2,3,5, Heather McLaughlin2,6,7, Peter Kraft8, Heidi L Rehm2,6,7, Gina M Peloso2,3, James G Wilson9, Adolfo Correa10, Jonathan G Seidman2,5, Christine E Seidman2,5,11,12, Sekar Kathiresan1,2,3, Robert C Green13,3,7,11.   

Abstract

In populations that have not been selected for family history of disease, it is unclear how commonly pathogenic variants (PVs) in disease-associated genes for rare Mendelian conditions are found and how often they are associated with clinical features of these conditions. We conducted independent, prospective analyses of participants in two community-based epidemiological studies to test the hypothesis that persons carrying PVs in any of 56 genes that lead to 24 dominantly inherited, actionable conditions are more likely to exhibit the clinical features of the corresponding diseases than those without PVs. Among 462 European American Framingham Heart Study (FHS) and 3223 African-American Jackson Heart Study (JHS) participants who were exome-sequenced, we identified and classified 642 and 4429 unique variants, respectively, in these 56 genes while blinded to clinical data. In the same participants, we ascertained related clinical features from the participants' clinical history of cancer and most recent echocardiograms, electrocardiograms, and lipid measurements, without knowledge of variant classification. PVs were found in 5 FHS (1.1%) and 31 JHS (1.0%) participants. Carriers of PVs were more likely than expected, on the basis of incidence in noncarriers, to have related clinical features in both FHS (80.0% versus 12.4%) and JHS (26.9% versus 5.4%), yielding standardized incidence ratios of 6.4 [95% confidence interval (CI), 1.7 to 16.5; P = 7 × 10-4) in FHS and 4.7 (95% CI, 1.9 to 9.7; P = 3 × 10-4) in JHS. Individuals unselected for family history who carry PVs in 56 genes for actionable conditions have an increased aggregated risk of developing clinical features associated with the corresponding diseases.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2016        PMID: 27831900      PMCID: PMC5823271          DOI: 10.1126/scitranslmed.aag2367

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  165 in total

Review 1.  Population screening in the age of genomic medicine.

Authors:  Muin J Khoury; Linda L McCabe; Edward R B McCabe
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

2.  Sebaceous gland carcinoma of the eyelid masquerading as a cutaneous horn in Li--Fraumeni syndrome.

Authors:  S Baumüller; M C Herwig; E Mangold; F C Holz; K U Loeffler
Journal:  Br J Ophthalmol       Date:  2011-10       Impact factor: 4.638

3.  A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Paul A van der Zwaag; Jan D H Jongbloed; Maarten P van den Berg; Jasper J van der Smagt; Roselie Jongbloed; Hennie Bikker; Robert M W Hofstra; J Peter van Tintelen
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

4.  Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy.

Authors:  Adam J Saltzman; Debora Mancini-DiNardo; Chumei Li; Wendy K Chung; Carolyn Y Ho; Stephanie Hurst; Julia Wynn; Melanie Care; Robert M Hamilton; Gregor W Seidman; Joshua Gorham; Barbara McDonough; Elizabeth Sparks; J G Seidman; Christine E Seidman; Heidi L Rehm
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

5.  Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing.

Authors:  David J Tester; Melissa L Will; Carla M Haglund; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2005-05       Impact factor: 6.343

6.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

7.  LQTS in Northern BC: homozygosity for KCNQ1 V205M presents with a more severe cardiac phenotype but with minimal impact on auditory function.

Authors:  H A Jackson; S McIntosh; B Whittome; S Asuri; B Casey; C Kerr; A Tang; L T Arbour
Journal:  Clin Genet       Date:  2013-07-30       Impact factor: 4.438

8.  High prevalence of four long QT syndrome founder mutations in the Finnish population.

Authors:  Annukka Marjamaa; Veikko Salomaa; Christopher Newton-Cheh; Kimmo Porthan; Antti Reunanen; Hannu Karanko; Antti Jula; Päivi Lahermo; Heikki Väänänen; Lauri Toivonen; Heikki Swan; Matti Viitasalo; Markku S Nieminen; Leena Peltonen; Lasse Oikarinen; Aarno Palotie; Kimmo Kontula
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

9.  Taxonomizing, sizing, and overcoming the incidentalome.

Authors:  Isaac S Kohane; Michael Hsing; Sek Won Kong
Journal:  Genet Med       Date:  2012-02-09       Impact factor: 8.822

10.  The UCSC Genome Browser database: 2014 update.

Authors:  Donna Karolchik; Galt P Barber; Jonathan Casper; Hiram Clawson; Melissa S Cline; Mark Diekhans; Timothy R Dreszer; Pauline A Fujita; Luvina Guruvadoo; Maximilian Haeussler; Rachel A Harte; Steve Heitner; Angie S Hinrichs; Katrina Learned; Brian T Lee; Chin H Li; Brian J Raney; Brooke Rhead; Kate R Rosenbloom; Cricket A Sloan; Matthew L Speir; Ann S Zweig; David Haussler; Robert M Kuhn; W James Kent
Journal:  Nucleic Acids Res       Date:  2013-11-21       Impact factor: 16.971

View more
  25 in total

Review 1.  Management of Secondary Genomic Findings.

Authors:  Alexander E Katz; Robert L Nussbaum; Benjamin D Solomon; Heidi L Rehm; Marc S Williams; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2020-07-02       Impact factor: 11.025

Review 2.  Ethical considerations in genomic testing for hematologic disorders.

Authors:  Jonathan M Marron; Steven Joffe
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

3.  1 in 38 individuals at risk of a dominant medically actionable disease.

Authors:  Lonneke Haer-Wigman; Vyne van der Schoot; Ilse Feenstra; Anneke T Vulto-van Silfhout; Christian Gilissen; Han G Brunner; Lisenka E L M Vissers; Helger G Yntema
Journal:  Eur J Hum Genet       Date:  2018-10-05       Impact factor: 4.246

4.  Actionable secondary findings from whole-genome sequencing of 954 East Asians.

Authors:  Clara Sze-Man Tang; Saloni Dattani; Man-Ting So; Stacey S Cherny; Paul K H Tam; Pak C Sham; Maria-Mercè Garcia-Barcelo
Journal:  Hum Genet       Date:  2017-11-11       Impact factor: 4.132

5.  Penetrance and the Healthy Elderly.

Authors:  Paul Lacaze; Ingrid Winship; John McNeil
Journal:  Genet Test Mol Biomarkers       Date:  2017-09-06

6.  Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic.

Authors:  Shana E Gleeson; Richard N Formica; Ethan P Marin
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-28       Impact factor: 8.237

Review 7.  Reconciling Opportunistic and Population Screening in Clinical Genomics.

Authors:  Kyle B Brothers; Jason L Vassy; Robert C Green
Journal:  Mayo Clin Proc       Date:  2019-01       Impact factor: 7.616

Review 8.  Building evidence and measuring clinical outcomes for genomic medicine.

Authors:  Josh F Peterson; Dan M Roden; Lori A Orlando; Andrea H Ramirez; George A Mensah; Marc S Williams
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

9.  Policy brief: Improve coverage of newborn genetic screening to include the Recommended Uniform Screening Panel and newborn screening registry.

Authors:  Angela Starkweather; Bernice Coleman; Veronica Barcelona de Mendoza; Mei Fu; Jacquelyn Taylor; Wendy Henderson; Carole Kenner; Deborah Walker; Linda Amankwaa; Cindy Anderson
Journal:  Nurs Outlook       Date:  2017-05-08       Impact factor: 3.250

Review 10.  70-year legacy of the Framingham Heart Study.

Authors:  Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan
Journal:  Nat Rev Cardiol       Date:  2019-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.